| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: kazuho@fmu.ac.jp
Three-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors, known as statins, induce skeletal muscle injury including myalgia, myositis, and rhabdomyolysis. The mechanism of this myotoxicity remains unknown. This study examined the effect of statins on single skeletal myofibers enzymatically isolated from the rat flexor digitorum brevis muscles. Fluvastatin and pravastatin induced the formation of numerous vacuoles in the myofibers after 72 h of treatment. This effect progressed in a time- and concentration-dependent manner and, consequently, cell death occurred after 120 h. Electron micrographs revealed craters along the sarcolemma and swelling of the sarcoplasmic reticula and mitochondria, in addition to intracellular vacuoles. When caffeine was added after 72 h of fluvastatin treatment, contractile shortening of statin-treated myofibers was significantly attenuated and blebs formed on the surface of the myofibers. The coapplication of geranylgeranylpyrophosphate (GGPP) with fluvastatin prevented the morphological changes, while that of farnesylpyrophosphate (FPP) was ineffective. Furthermore, perillyl alcohol, an inhibitor of Rab geranylgeranyl transferase and geranylgeranyl transferase-I (GGTase-I), mimicked the effect of statins, while a specific GGTase-I inhibitor (GGTI-298) or a farnesyl transferase inhibitor (FTI-277) failed to do so. These results suggest that the inactivation of Rab GTPase, which involved in intracellular membrane transport, is a crucial factor in statin-induced-morphological abnormality in skeletal muscle fibers.--Sakamoto, K., Honda, T., Yokoya, S., Waguri, S., Kimura, J. Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers.
This article has been cited by other articles:
|
|
 |
|
  K. M. Sane, M. Mynderse, D. T. LaLonde, I. S. Dean, J. W. Wojtkowiak, F. Fouad, R. F. Borch, J. J. Reiners Jr., R. A. Gibbs, and R. R. Mattingly A Novel Geranylgeranyl Transferase Inhibitor in Combination with Lovastatin Inhibits Proliferation and Induces Autophagy in STS-26T MPNST Cells J. Pharmacol. Exp. Ther., April 1, 2010; 333(1): 23 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Knauer, B. L. Urquhart, H. E. Meyer zu Schwabedissen, U. I. Schwarz, C. J. Lemke, B. F. Leake, R. B. Kim, and R. G. Tirona Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins Circ. Res., February 5, 2010; 106(2): 297 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cao, J.-i. Hanai, P. Tanksale, S. Imamura, V. P. Sukhatme, and S. H. Lecker Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect FASEB J, September 1, 2009; 23(9): 2844 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Joy and R. A. Hegele Narrative Review: Statin-Related Myopathy Ann Intern Med, June 16, 2009; 150(12): 858 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Murinson and N. J. Maragakis Fluvastatin, Rhabdomyolysis, and Myotoxicity Mayo Clin. Proc., November 1, 2008; 83(11): 1296 - 1296. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
